The medical community is witnessing a historic turning point with the emergence of psychedelic-derived compounds in the pipeline for 2026. Investigational treatments like MM120—a precisamente controlled dose of a lysergic acid diethylamide (LSD) derivative—are moving through late-stage clinical trials for generalized anxiety disorder. Unlike traditional daily pills, these therapies...
English
Arabic
French
Spanish
Portuguese
Deutsch
Turkish
Dutch
Italiano
Romaian
Portuguese (Brazil)
Greek